The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection
Open accessAbstract
Azithromycin is a potent macrolide antibiotic with poorly understood antiinflammatory properties. Long-term use of azithromycin in patients with chronic inflammatory lung diseases, such as cystic fibrosis (CF), results in improved outcomes. Paradoxically, a recent study reported that azithromycin use in patients with CF is associated with increased infection with nontuberculous mycobacteria (NTM). Here, we confirm that long-term azithromycin use by adults with CF is associated with the development of infection with NTM, particularly the multi-drug-resistant species Mycobacterium abscessus, and identify an underlying mechanism. We found that in primary human macrophages, concentrations of azithromycin achieved during therapeutic dosing blocked autophagosome clearance by preventing lysosomal acidification, thereby impairing autophagic and phagosomal degradation. As a consequence, azithromycin treatment inhibited intracellular killing of mycobacteria within macrophages and resulted in chronic infection with NTM in mice. Our findings emphasize the essential role for autophagy in the host response to infection with NTM, reveal why chronic use of azithromycin may predispose to mycobacterial disease, and highlight the dangers of inadvertent pharmacological blockade of autophagy in patients at risk of infection with drug-resistant pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.
Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., & Yoshimori, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.21.5720 · Cited by 6,605
Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-571st · Cited by 6,110
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347 · cited 1×
“Moreover, the azithromycin-induced rise in LC3-II was not accompanied by decreases in mTOR-dependent signaling (monitored by phosphorylation of p70S6 kinase and S6), a major negative regulator of autophagosome synthesis (14), but was associated — in both HeLa cells and primary macrophages — with Figure 1 Azithromycin…”
BackgroundSelf-citationGutierrez, M. G., Master, S. S., Singh, S. B., Taylor, G. A., Colombo, M. I., & Deretic, V. (2004) · Cell · doi:10.1016/j.cell.2004.11.038 · Cited by 2,252 · cited 5×
“Since intracellular killing of mycobacteria by macrophages is critically enhanced by IFN-γ–induced autophagy (20), we examined the effect of azithromycin on autophagosomal flux triggered by this cytokine.”
BackgroundInfluentialGuidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes
Klionsky, D. J., Abeliovich, H., Agostinis, P., Agrawal, D. K., Aliev, G., Askew, D. S., Baba, M., Baehrecke, E. H., Bahr, B. A., Ballabio, A., et al. (2008) · Autophagy · doi:10.4161/auto.5338 · Cited by 2,230 · cited 4×
“We next examined whether inhibition of LC3-II clearance by azithromycin was caused by failure of autophagosome-lysosome fusion, as seen with long-term treatment with BafA1 treatment (11), or failure of lysosomal function, a mechanism we recently reported (19).”
BackgroundInfluentialSelf-citationThe role of autophagy in cancer development and response to therapy
Kondo, Y., Kanzawa, T., Sawaya, R., & Kondo, S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1692 · Cited by 1,654
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429
Self-citationp62 at the crossroads of autophagy, apoptosis, and cancer
Moscat, J., & Diaz-Meco, M. T. (2009) · Cell · doi:10.1016/j.cell.2009.05.023 · Cited by 1,073
Human IRGM Induces Autophagy to Eliminate Intracellular Mycobacteria
Singh, S. B., Davis, A. S., Taylor, G. A., & Deretic, V. (2006) · Science · doi:10.1126/science.1129577 · Cited by 915 · cited 2×
“Although the mechanism underlying these effects remains to be elucidated, the net result will likely be further inhibition of autophagic killing (25, 26).”
BackgroundNash, K. A., Brown-Elliott, B. A., & Wallace, R. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01275-08 · Cited by 638
Cited by
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., Abel, S., Abeliovich, H., Abildgaard, M. H., Abudu, Y. P., Acevedo-Arozena, A., et al. (2021) · Autophagy · doi:10.1080/15548627.2020.1797280 · Cited by 2,897
Self-citationAutophagy modulation as a potential therapeutic target for diverse diseases
Rubinsztein, D. C., Codogno, P., & Levine, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3802 · Cited by 1,437
Self-citationBeceiro, A., Tomás, M., & Bou, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00059-12 · Cited by 1,070
Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles
Galluzzi, L., Bravo-San Pedro, J. M., Levine, B., Green, D. R., & Kroemer, G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.22 · Cited by 842
Haworth, C. S., Banks, J., Capstick, T., Fisher, A. J., Gorsuch, T., Laurenson, I. F., Leitch, A., Loebinger, M. R., Milburn, H. J., Nightingale, M., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2017-210927 · Cited by 785
Self-citationLysosomes as a therapeutic target
Bonam, S. R., Wang, F., & Muller, S. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0036-1 · Cited by 759
Bryant, J. M., Grogono, D. M., Greaves, D., Foweraker, J., Roddick, I., Inns, T., Reacher, M., Haworth, C. S., Curran, M. D., Harris, S. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60632-7 · Cited by 694
Self-citationAzithromycin: Mechanisms of action and their relevance for clinical applications
Parnham, M. J., Haber, V. E., Giamarellos-Bourboulis, E. J., Perletti, G., Verleden, G. M., & Vos, R. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.003 · Cited by 661
Wong, C., Jayaram, L., Karalus, N., Eaton, T., Tong, C., Hockey, H., Milne, D., Fergusson, W., Tuffery, C., Sexton, P., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60953-2 · Cited by 600
Cystic fibrosis: a mucosal immunodeficiency syndrome
Cohen, T. S., & Prince, A. (2012) · Nature Medicine · doi:10.1038/nm.2715 · Cited by 484
The Rise of Non-Tuberculosis Mycobacterial Lung Disease
Ratnatunga, C. N., Lutzky, V. P., Kupz, A., Doolan, D. L., Reid, D. W., Field, M., Bell, S. C., Thomson, R. M., & Miles, J. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00303 · Cited by 483
Crosstalk between autophagy and inflammatory signalling pathways: balancing defence and homeostasis
Cadwell, K. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.100 · Cited by 475
Treatment of lung infection in patients with cystic fibrosis: Current and future strategies
Döring, G., Flume, P., Heijerman, H., & Elborn, J. S. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.10.004 · Cited by 474
Floto, R. A., Olivier, K. N., Saiman, L., Daley, C. L., Herrmann, J.-L., Nick, J. A., Noone, P. G., Bilton, D., Corris, P., Gibson, R. L., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207360 · Cited by 466
Self-citationFloto, R. A., Olivier, K. N., Saiman, L., Daley, C. L., Herrmann, J.-L., Nick, J. A., Noone, P. G., Bilton, D., Corris, P., Gibson, R. L., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207983 · Cited by 462
Self-citationShapiro, A. J., Zariwala, M. A., Ferkol, T., Davis, S. D., Sagel, S. D., Dell, S. D., Rosenfeld, M., Olivier, K. N., Milla, C., Daniel, S. J., et al. (2016) · Pediatric Pulmonology · doi:10.1002/ppul.23304 · Cited by 457
Autophagy and cellular immune responses
Ma, Y., Galluzzi, L., Zitvogel, L., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.017 · Cited by 447
Rapid repurposing of drugs for COVID-19
Guy, R. K., DiPaola, R. S., Romanelli, F., & Dutch, R. E. (2020) · Science · doi:10.1126/science.abb9332 · Cited by 304
Advancing host-directed therapy for tuberculosis
Wallis, R. S., & Hafner, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3813 · Cited by 291
Rogers, G. B., Bruce, K. D., Martin, M. L., Burr, L. D., & Serisier, D. J. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70213-9 · Cited by 217
Therapeutic targeting of autophagy in neurodegenerative and infectious diseases
Rubinsztein, D. C., Bento, C. F., & Deretic, V. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150956 · Cited by 202
Self-citationAutophagy in Pulmonary Diseases
Nakahira, K., Pabon Porras, M. A., & Choi, A. M. K. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201512-2468so · Cited by 78
Cystic fibrosis – Ten promising therapeutic approaches in the current era of care
Somayaji, R., Nichols, D. P., & Bell, S. C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1805733 · Cited by 12
Metadata
- Authors
- Renna, M., Schaffner, C., Brown, K., Shang, S., Tamayo, M. H., Hegyi, K., Grimsey, N. J., Cusens, D., Coulter, S., Cooper, J., Bowden, A. R., Newton, S. M., Kampmann, B., Helm, J., Jones, A., Haworth, C. S., Basaraba, R. J., DeGroote, M. A., Ordway, D. J., Rubinsztein, D. C., & Floto, R. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2011-09-01
- Volume
- 121
- Issue
- 9
- Pages
- 3554-3563
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2016283787
- Cited by
- 314
- References
- 31
- FWCI
- 18.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.